Fml

Iron Deficiency Anemia, Iron deficiency, Breastfeeding + 8 more
Treatment
1 FDA approval
20 Active Studies for Fml

What is Fml

Ferrous sulfate anhydrousThe Generic name of this drug
Treatment SummaryFerrous sulfate is a synthetic drug commonly used to treat iron deficiency anemia. It is considered the best oral iron therapy to address iron deficiencies in young children, infants, and women of childbearing age. Ferrous sulfate is widely used in the UK and many other countries to treat iron deficiency anemia.
Tri-Vitamin with iron and fluorideis the brand name
image of different drug pills on a surface
Fml Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Tri-Vitamin with iron and fluoride
Ferrous sulfate anhydrous
1997
0

Approved as Treatment by the FDA

Ferrous sulfate anhydrous, also called Tri-Vitamin with iron and fluoride, is approved by the FDA for 1 uses which include Iron Deficiency Anemia .
Iron Deficiency Anemia

Effectiveness

How Fml Affects PatientsFerrous sulfate is a supplement that replaces the iron usually found in hemoglobin and myoglobin. Iron is important for transporting oxygen, providing energy, and protecting our cells from damage. It also helps with tissue growth and keeping our DNA healthy.
How Fml works in the bodyIron plays an important role in the body, helping form red blood cells that carry oxygen around. When the body cannot produce enough normal red blood cells due to a lack of iron, it is known as iron deficiency anemia. Symptoms of iron deficiency anemia include fatigue, breathlessness, palpitations, dizziness, and headache. Taking iron supplements can help restore the body's iron levels. Iron is transported by a protein called DMT1 into macrophages, where it is stored or transported out of the macrophage. It is then oxidized and taken up by transferrin for transport in the serum to sites like the bone

When to interrupt dosage

The recommended dosage of Fml is contingent upon the diagnosed disorder, including hypochromic anemia, Lactation and Iron deficiency anemia. The measure of dosage also varies as per the technique of delivery (e.g. Tablet - Oral or Tablet, extended release - Oral) specified in the table below.
Condition
Dosage
Administration
Iron replacement therapy
, 0.05 mg/mg, 300.0 mg, 5.0 mg, 18.0 mg, 27.0 mg, 65.0 mg, 4.0 mg, 105.0 mg, 0.56 mg, 125.0 mg/mL, 60.0 mg, 15.0 mg/mL, 30.0 mg, 35.0 mg, 50.0 mg, 9.5 mg, 10.0 mg/mL, 3.6 mg/mL, 525.0 mg, 324.0 mg, 220.0 mg/mL, 325.0 mg, 0.00063 mg/mg, 11.0 mg/mL, 9.5 mg/mL
Tablet - Oral, Tablet, extended release - Oral, , Tablet, effervescent - Oral, Oral, Capsule - Oral, Tablet, extended release, Tablet, Tablet, effervescent, Tablet, coated - Oral, Topical, Solution / drops, Solution, Liquid, Tablet, film coated, Solution - Oral, Liquid - Oral, Lotion, Powder, Powder - Oral, Elixir - Oral, Solution / drops - Oral, Liquid; Tablet - Oral, Tablet, coated, Tablet, delayed release, Capsule, Tablet, film coated - Oral, Tablet, delayed release - Oral, Lotion - Topical, Capsule, extended release - Oral, Elixir, Capsule, extended release, Liquid; Tablet
Folic Acid Deficiency
, 0.05 mg/mg, 300.0 mg, 5.0 mg, 18.0 mg, 27.0 mg, 65.0 mg, 4.0 mg, 105.0 mg, 0.56 mg, 125.0 mg/mL, 60.0 mg, 15.0 mg/mL, 30.0 mg, 35.0 mg, 50.0 mg, 9.5 mg, 10.0 mg/mL, 3.6 mg/mL, 525.0 mg, 324.0 mg, 220.0 mg/mL, 325.0 mg, 0.00063 mg/mg, 11.0 mg/mL, 9.5 mg/mL
Tablet - Oral, Tablet, extended release - Oral, , Tablet, effervescent - Oral, Oral, Capsule - Oral, Tablet, extended release, Tablet, Tablet, effervescent, Tablet, coated - Oral, Topical, Solution / drops, Solution, Liquid, Tablet, film coated, Solution - Oral, Liquid - Oral, Lotion, Powder, Powder - Oral, Elixir - Oral, Solution / drops - Oral, Liquid; Tablet - Oral, Tablet, coated, Tablet, delayed release, Capsule, Tablet, film coated - Oral, Tablet, delayed release - Oral, Lotion - Topical, Capsule, extended release - Oral, Elixir, Capsule, extended release, Liquid; Tablet
Latent Iron Deficiency
, 0.05 mg/mg, 300.0 mg, 5.0 mg, 18.0 mg, 27.0 mg, 65.0 mg, 4.0 mg, 105.0 mg, 0.56 mg, 125.0 mg/mL, 60.0 mg, 15.0 mg/mL, 30.0 mg, 35.0 mg, 50.0 mg, 9.5 mg, 10.0 mg/mL, 3.6 mg/mL, 525.0 mg, 324.0 mg, 220.0 mg/mL, 325.0 mg, 0.00063 mg/mg, 11.0 mg/mL, 9.5 mg/mL
Tablet - Oral, Tablet, extended release - Oral, , Tablet, effervescent - Oral, Oral, Capsule - Oral, Tablet, extended release, Tablet, Tablet, effervescent, Tablet, coated - Oral, Topical, Solution / drops, Solution, Liquid, Tablet, film coated, Solution - Oral, Liquid - Oral, Lotion, Powder, Powder - Oral, Elixir - Oral, Solution / drops - Oral, Liquid; Tablet - Oral, Tablet, coated, Tablet, delayed release, Capsule, Tablet, film coated - Oral, Tablet, delayed release - Oral, Lotion - Topical, Capsule, extended release - Oral, Elixir, Capsule, extended release, Liquid; Tablet
breastfeeding women
, 0.05 mg/mg, 300.0 mg, 5.0 mg, 18.0 mg, 27.0 mg, 65.0 mg, 4.0 mg, 105.0 mg, 0.56 mg, 125.0 mg/mL, 60.0 mg, 15.0 mg/mL, 30.0 mg, 35.0 mg, 50.0 mg, 9.5 mg, 10.0 mg/mL, 3.6 mg/mL, 525.0 mg, 324.0 mg, 220.0 mg/mL, 325.0 mg, 0.00063 mg/mg, 11.0 mg/mL, 9.5 mg/mL
Tablet - Oral, Tablet, extended release - Oral, , Tablet, effervescent - Oral, Oral, Capsule - Oral, Tablet, extended release, Tablet, Tablet, effervescent, Tablet, coated - Oral, Topical, Solution / drops, Solution, Liquid, Tablet, film coated, Solution - Oral, Liquid - Oral, Lotion, Powder, Powder - Oral, Elixir - Oral, Solution / drops - Oral, Liquid; Tablet - Oral, Tablet, coated, Tablet, delayed release, Capsule, Tablet, film coated - Oral, Tablet, delayed release - Oral, Lotion - Topical, Capsule, extended release - Oral, Elixir, Capsule, extended release, Liquid; Tablet
hypochromic anemia
, 0.05 mg/mg, 300.0 mg, 5.0 mg, 18.0 mg, 27.0 mg, 65.0 mg, 4.0 mg, 105.0 mg, 0.56 mg, 125.0 mg/mL, 60.0 mg, 15.0 mg/mL, 30.0 mg, 35.0 mg, 50.0 mg, 9.5 mg, 10.0 mg/mL, 3.6 mg/mL, 525.0 mg, 324.0 mg, 220.0 mg/mL, 325.0 mg, 0.00063 mg/mg, 11.0 mg/mL, 9.5 mg/mL
Tablet - Oral, Tablet, extended release - Oral, , Tablet, effervescent - Oral, Oral, Capsule - Oral, Tablet, extended release, Tablet, Tablet, effervescent, Tablet, coated - Oral, Topical, Solution / drops, Solution, Liquid, Tablet, film coated, Solution - Oral, Liquid - Oral, Lotion, Powder, Powder - Oral, Elixir - Oral, Solution / drops - Oral, Liquid; Tablet - Oral, Tablet, coated, Tablet, delayed release, Capsule, Tablet, film coated - Oral, Tablet, delayed release - Oral, Lotion - Topical, Capsule, extended release - Oral, Elixir, Capsule, extended release, Liquid; Tablet
Iron Deficiency Anemia
, 0.05 mg/mg, 300.0 mg, 5.0 mg, 18.0 mg, 27.0 mg, 65.0 mg, 4.0 mg, 105.0 mg, 0.56 mg, 125.0 mg/mL, 60.0 mg, 15.0 mg/mL, 30.0 mg, 35.0 mg, 50.0 mg, 9.5 mg, 10.0 mg/mL, 3.6 mg/mL, 525.0 mg, 324.0 mg, 220.0 mg/mL, 325.0 mg, 0.00063 mg/mg, 11.0 mg/mL, 9.5 mg/mL
Tablet - Oral, Tablet, extended release - Oral, , Tablet, effervescent - Oral, Oral, Capsule - Oral, Tablet, extended release, Tablet, Tablet, effervescent, Tablet, coated - Oral, Topical, Solution / drops, Solution, Liquid, Tablet, film coated, Solution - Oral, Liquid - Oral, Lotion, Powder, Powder - Oral, Elixir - Oral, Solution / drops - Oral, Liquid; Tablet - Oral, Tablet, coated, Tablet, delayed release, Capsule, Tablet, film coated - Oral, Tablet, delayed release - Oral, Lotion - Topical, Capsule, extended release - Oral, Elixir, Capsule, extended release, Liquid; Tablet
Iron deficiency
, 0.05 mg/mg, 300.0 mg, 5.0 mg, 18.0 mg, 27.0 mg, 65.0 mg, 4.0 mg, 105.0 mg, 0.56 mg, 125.0 mg/mL, 60.0 mg, 15.0 mg/mL, 30.0 mg, 35.0 mg, 50.0 mg, 9.5 mg, 10.0 mg/mL, 3.6 mg/mL, 525.0 mg, 324.0 mg, 220.0 mg/mL, 325.0 mg, 0.00063 mg/mg, 11.0 mg/mL, 9.5 mg/mL
Tablet - Oral, Tablet, extended release - Oral, , Tablet, effervescent - Oral, Oral, Capsule - Oral, Tablet, extended release, Tablet, Tablet, effervescent, Tablet, coated - Oral, Topical, Solution / drops, Solution, Liquid, Tablet, film coated, Solution - Oral, Liquid - Oral, Lotion, Powder, Powder - Oral, Elixir - Oral, Solution / drops - Oral, Liquid; Tablet - Oral, Tablet, coated, Tablet, delayed release, Capsule, Tablet, film coated - Oral, Tablet, delayed release - Oral, Lotion - Topical, Capsule, extended release - Oral, Elixir, Capsule, extended release, Liquid; Tablet
Breastfeeding
, 0.05 mg/mg, 300.0 mg, 5.0 mg, 18.0 mg, 27.0 mg, 65.0 mg, 4.0 mg, 105.0 mg, 0.56 mg, 125.0 mg/mL, 60.0 mg, 15.0 mg/mL, 30.0 mg, 35.0 mg, 50.0 mg, 9.5 mg, 10.0 mg/mL, 3.6 mg/mL, 525.0 mg, 324.0 mg, 220.0 mg/mL, 325.0 mg, 0.00063 mg/mg, 11.0 mg/mL, 9.5 mg/mL
Tablet - Oral, Tablet, extended release - Oral, , Tablet, effervescent - Oral, Oral, Capsule - Oral, Tablet, extended release, Tablet, Tablet, effervescent, Tablet, coated - Oral, Topical, Solution / drops, Solution, Liquid, Tablet, film coated, Solution - Oral, Liquid - Oral, Lotion, Powder, Powder - Oral, Elixir - Oral, Solution / drops - Oral, Liquid; Tablet - Oral, Tablet, coated, Tablet, delayed release, Capsule, Tablet, film coated - Oral, Tablet, delayed release - Oral, Lotion - Topical, Capsule, extended release - Oral, Elixir, Capsule, extended release, Liquid; Tablet
Pregnancy
, 0.05 mg/mg, 300.0 mg, 5.0 mg, 18.0 mg, 27.0 mg, 65.0 mg, 4.0 mg, 105.0 mg, 0.56 mg, 125.0 mg/mL, 60.0 mg, 15.0 mg/mL, 30.0 mg, 35.0 mg, 50.0 mg, 9.5 mg, 10.0 mg/mL, 3.6 mg/mL, 525.0 mg, 324.0 mg, 220.0 mg/mL, 325.0 mg, 0.00063 mg/mg, 11.0 mg/mL, 9.5 mg/mL
Tablet - Oral, Tablet, extended release - Oral, , Tablet, effervescent - Oral, Oral, Capsule - Oral, Tablet, extended release, Tablet, Tablet, effervescent, Tablet, coated - Oral, Topical, Solution / drops, Solution, Liquid, Tablet, film coated, Solution - Oral, Liquid - Oral, Lotion, Powder, Powder - Oral, Elixir - Oral, Solution / drops - Oral, Liquid; Tablet - Oral, Tablet, coated, Tablet, delayed release, Capsule, Tablet, film coated - Oral, Tablet, delayed release - Oral, Lotion - Topical, Capsule, extended release - Oral, Elixir, Capsule, extended release, Liquid; Tablet
Folate deficiency
, 0.05 mg/mg, 300.0 mg, 5.0 mg, 18.0 mg, 27.0 mg, 65.0 mg, 4.0 mg, 105.0 mg, 0.56 mg, 125.0 mg/mL, 60.0 mg, 15.0 mg/mL, 30.0 mg, 35.0 mg, 50.0 mg, 9.5 mg, 10.0 mg/mL, 3.6 mg/mL, 525.0 mg, 324.0 mg, 220.0 mg/mL, 325.0 mg, 0.00063 mg/mg, 11.0 mg/mL, 9.5 mg/mL
Tablet - Oral, Tablet, extended release - Oral, , Tablet, effervescent - Oral, Oral, Capsule - Oral, Tablet, extended release, Tablet, Tablet, effervescent, Tablet, coated - Oral, Topical, Solution / drops, Solution, Liquid, Tablet, film coated, Solution - Oral, Liquid - Oral, Lotion, Powder, Powder - Oral, Elixir - Oral, Solution / drops - Oral, Liquid; Tablet - Oral, Tablet, coated, Tablet, delayed release, Capsule, Tablet, film coated - Oral, Tablet, delayed release - Oral, Lotion - Topical, Capsule, extended release - Oral, Elixir, Capsule, extended release, Liquid; Tablet
Iron Deficiency Anemia
, 0.05 mg/mg, 300.0 mg, 5.0 mg, 18.0 mg, 27.0 mg, 65.0 mg, 4.0 mg, 105.0 mg, 0.56 mg, 125.0 mg/mL, 60.0 mg, 15.0 mg/mL, 30.0 mg, 35.0 mg, 50.0 mg, 9.5 mg, 10.0 mg/mL, 3.6 mg/mL, 525.0 mg, 324.0 mg, 220.0 mg/mL, 325.0 mg, 0.00063 mg/mg, 11.0 mg/mL, 9.5 mg/mL
Tablet - Oral, Tablet, extended release - Oral, , Tablet, effervescent - Oral, Oral, Capsule - Oral, Tablet, extended release, Tablet, Tablet, effervescent, Tablet, coated - Oral, Topical, Solution / drops, Solution, Liquid, Tablet, film coated, Solution - Oral, Liquid - Oral, Lotion, Powder, Powder - Oral, Elixir - Oral, Solution / drops - Oral, Liquid; Tablet - Oral, Tablet, coated, Tablet, delayed release, Capsule, Tablet, film coated - Oral, Tablet, delayed release - Oral, Lotion - Topical, Capsule, extended release - Oral, Elixir, Capsule, extended release, Liquid; Tablet

Warnings

Fml Contraindications
Condition
Risk Level
Notes
Non-iron deficiency anemia
Do Not Combine
Hemosiderosis
Do Not Combine
Hemochromatosis
Do Not Combine
There are 20 known major drug interactions with Fml.
Common Fml Drug Interactions
Drug Name
Risk Level
Description
Raltegravir
Major
The serum concentration of Raltegravir can be decreased when it is combined with Ferrous sulfate anhydrous.
Technetium Tc-99m oxidronate
Major
Ferrous sulfate anhydrous can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.
3-Aza-2,3-Dihydrogeranyl Diphosphate
Minor
Ferrous sulfate anhydrous can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium phosphate dihydrate
Minor
Ferrous sulfate anhydrous can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric pyrophosphate
Minor
Ferrous sulfate anhydrous can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fml Toxicity & Overdose RiskThe amount of iron in ferrous sulfate that is considered safe for humans is up to 20mg/kg, while an amount between 20-60mg/kg can lead to mild toxicity. Anything higher than 60mg/kg can cause severe symptoms. People who have overdosed on ferrous sulfate may experience nausea, gas, abdominal pain, diarrhea, constipation, dark stools, bluish lips, fingertips, and palms, drowsiness, fast heartbeat, seizures, acidosis, liver injury, and heart problems. If the patient is unresponsive or having seizures, doctors may perform gastric lavage with sodium bic
image of a doctor in a lab doing drug, clinical research

Fml Novel Uses: Which Conditions Have a Clinical Trial Featuring Fml?

171 active trials are ongoing to investigate the use of Fml for Iron Deficiency Anemia, Iron replenishment and Folate deficiency therapy.
Condition
Clinical Trials
Trial Phases
hypochromic anemia
0 Actively Recruiting
Latent Iron Deficiency
0 Actively Recruiting
Iron deficiency
2 Actively Recruiting
Phase 2, Not Applicable
breastfeeding women
0 Actively Recruiting
Folic Acid Deficiency
0 Actively Recruiting
Breastfeeding
21 Actively Recruiting
Not Applicable, Phase 4, Phase 2
Folate deficiency
0 Actively Recruiting
Pregnancy
43 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Phase 1, Phase 4
Iron replacement therapy
0 Actively Recruiting
Iron Deficiency Anemia
12 Actively Recruiting
Phase 3, Phase 4, Not Applicable, Phase 2
Iron Deficiency Anemia
107 Actively Recruiting
Phase 1, Not Applicable, Phase 2, Phase 3, Phase 4

Patient Q&A Section about fml

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Fml

Have you considered Fml clinical trials? We made a collection of clinical trials featuring Fml, we think they might fit your search criteria.
Have you considered Fml clinical trials? We made a collection of clinical trials featuring Fml, we think they might fit your search criteria.
Have you considered Fml clinical trials? We made a collection of clinical trials featuring Fml, we think they might fit your search criteria.